Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641912 · ClinicalTrials.gov registry record · NA
Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
A NA study of Xerostomia, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT02641912: Completed NA study of Xerostomia, sponsored by GlaxoSmithKline.
NCT02641912 is a NA study of Xerostomia that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants, above the 88-participant average among 13 other Xerostomia trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02641912, a NA study of Xerostomia, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a single center, 7-day, examiner blind, two treatment-arm, randomized, stratified (Sjogren's Syndrome status \[Y/N\]), parallel group study conducted in participants experiencing dry mouth symptoms. This study is designed to investigate the effect of an experimental mouthwash formulation in providing relief of dry mouth symptoms.
Primary Outcome
Participants answered question 1 'Relieving the discomfort of dry mouth' in PPAQ3 and rated this question on scale as follows: N/A = Not Applicable; 1 = poor; 2 = fair; 3 = good; 4 = very good; 5 = excellent. Scale score was averaged to calculate the response.
Conditions Studied
Interventions
- OTHER Biotene mouthwash
- OTHER Mineral Water
Study Locations (1)
Massachusetts
- GSK Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2016-04-15 |
| Phase | NA |
What the finished NCT02641912 record still lists
NCT02641912 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 13 other Xerostomia trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Xerostomia appearing as the primary indexed condition, and to 2 interventions - of which Biotene mouthwash is the first listed.
NCT02641912 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02641912 about?
NCT02641912 is a clinical study titled "Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms". This will be a single center, 7-day, examiner blind, two treatment-arm, randomized, stratified (Sjogren's Syndrome status \[Y/N\]), parallel group study conducted in participants experiencing dry mouth symptoms. This study is designed to investigate the effect of an experimental mouthwash formulatio...
What is the current status of trial NCT02641912?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2016-03-09. Estimated completion is 2016-04-15.
What conditions does trial NCT02641912 study?
This clinical trial studies the following conditions: Xerostomia.
What interventions are being tested in trial NCT02641912?
The interventions under investigation include: Biotene mouthwash (OTHER), Mineral Water (OTHER).
Who is sponsoring clinical trial NCT02641912?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02641912 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Xerostomia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02641912's enrollment target sits among peer trials
100 2nd of 13 higher than 11 of 13 other Xerostomia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Xerostomia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis
ACTIVE NOT RECRUITING · NA
-
SaliPen Human Factors Study for OTC Labeling
COMPLETED · NA
-
Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects
COMPLETED · NA
-
Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray
COMPLETED · NA
-
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI